Evidence map›Paper›PMID 42186115›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Sabahat Iqbal, Cristina Bonet Olivares, Laura Rizzo, Thomas D Parker, Charis Wong, Benjamin R Underwood, James Carpenter, Ross Dunne, Vanessa Raymont, Alastair Reith and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sabahat IqbalImperial College London, London, UK.ORCID https://orcid.org/0000-0001-7658-6384
Cristina Bonet OlivaresImperial College London, London, UK.
Laura RizzoImperial College London, London, UK.
Thomas D ParkerImperial College London, London, UK.
Charis WongUniversity of Edinburgh, Edinburgh, UK.
Benjamin R UnderwoodDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
James CarpenterUniversity College London, London, UK.
Ross DunneGreater Manchester Mental Health Dementia Research Centre, Manchester, UK.
Vanessa RaymontUniversity of Oxford, Oxford, Oxfordshire, UK.
Alastair ReithBreckenfield Consulting Limited, London, UK.
Catherine J MummeryDementia Research Centre, Institute of Neurology, University College London, London, UK.
Eric H KarranUniversity College London, London, UK.
Fiona DucotterdUniversity College London, London, UK.
Gordon WilcockUniversity of Oxford (Emeritus), Oxford, UK.
Jeffrey L CummingsChambers-Grundy Center for Transformative Neuroscience, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Nevada, USA.
John T O'BrienDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Leah MursaleenAlzheimer's Research UK, Cambridge, UK.
Lon S SchneiderAlzheimer's Disease Research Center, Department of Psychiatry and the Behavioural Sciences, and Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Rik VandenbergheKU Leuven, Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium.
Malcolm MacleodInstitute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK.
Zunera KhanKings College London, London, UK.
Paresh MalhotraImperial College London, London, UK.
Suzanne ReevesDivision of Psychiatry, University College London, London, UK.

Funding

Alzheimer's Research UKUK National Institute for Health and Care Research (NIHR)
6 · The paper itself

Abstract

introductionThere is an urgent need to identify effective, safe, and affordable treatments for Alzheimer's disease (AD). Funded by the UK National Institute for Health and Care Research (NIHR), we developed a systematic drug prioritization pipeline to identify repurposed drug candidates for inclusion in a planned platform trial for clinical AD.

methodsThe wider AD community was invited to propose compounds using a standardized proposal template. Fourteen proposals were presented to an international expert panel, who independently ranked compounds based on biological plausibility, preclinical efficacy, safety, and trial feasibility. Extended drug summaries were compiled for shortlisted compounds, supported by ReLiSyR, a machine learning-supported systematic review tool.

resultsFollowing review in a second panel meeting, independent re-ranking identified the following compounds: atomoxetine (1st), metformin (2nd), isosorbide mononitrate and levetiracetam (joint 3rd). DISCUSSION: This robust drug prioritization pipeline will speed the identification and progression of promising candidates for therapeutic evaluation.

Indexed as

Alzheimer DiseaseClinical Trials as TopicDrug RepositioningAtomoxetine HydrochlorideHumansLevetiracetamMetforminAtomoxetine HydrochlorideLevetiracetamMetforminadaptive platform trialsAlzheimer's diseaseclinical trialscognitionneuropharmacologypharmacologyrepurposed drugs

Identifiers

PMID42186115
PMCPMC13239537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.